- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02595879
Triapin med kemoterapi och strålbehandling vid behandling av patienter med IB2-IVA livmoderhalscancer eller vaginal cancer
Fas I dosupptrappad biotillgänglighetsstudie av oral triapin i kombination med samtidig kemoradiation för lokalt avancerad livmoderhalscancer (LACC) och vaginal cancer
This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard treatment with cisplatin and radiation therapy may kill more cancer cells.
Studieöversikt
Status
Betingelser
- Avancerat vaginalt adenokarcinom
- Avancerat vaginalt adenoskvamöst karcinom
- Avancerat vaginalt skivepitelcancer
- Steg IB2 Livmoderhalscancer AJCC v6 och v7
- Steg II livmoderhalscancer AJCC v7
- Steg II Vaginal Cancer AJCC v6 och v7
- Steg III Vaginal Cancer AJCC v6 och v7
- Steg IIIB livmoderhalscancer AJCC v6 och v7
- Steg IVA livmoderhalscancer AJCC v6 och v7
- Steg IVA Vaginal Cancer AJCC v6 och v7
- Avancerat cervikalt adenokarcinom
- Avancerat cervikal adenosquamous karcinom
- Avancerat cervikalt skivepitelcancer
Intervention / Behandling
- Läkemedel: Cisplatin
- Procedur: Magnetic Resonance Imaging
- Övrig: Pharmacological Study
- Procedur: Biospecimen Collection
- Strålning: Intensity-Modulated Radiation Therapy
- Procedur: Computed Tomography
- Procedur: Positron Emission Tomography
- Strålning: Brachytherapy
- Strålning: External Beam Radiation Therapy
- Övrig: Fludeoxyglucose F-18
- Strålning: High-Dose Rate Brachytherapy
- Läkemedel: Triapine
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy.
II. To determine the oral bioavailability of triapine. III. To describe the pharmacokinetics (PK) of oral and intravenous triapine.
SECONDARY OBJECTIVES:
I. To determine whether the metabolic complete response (mCR) rate of oral triapine in combination with cisplatin chemoradiation using fludeoxyglucose F 18 (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) at post-therapy (3-month) is at least 70%.
II. To determine clinical overall response rate, progression-free survival, and overall survival.
III. To determine the correlation of methemoglobin proportion (%) and triapine pharmacokinetic exposure.
EXPLORATORY OBJECTIVE:
I. To determine whether active human immunodeficiency virus (HIV) antiretroviral therapy impacts the antitumor activity of triapine.
OUTLINE: This is a dose-escalation study of triapine.
Patients undergo pelvic external beam radiation therapy (EBRT) or intensity modulated radiation therapy (IMRT) 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of low dose rate (LDR) brachytherapy in week 6 or 5 fractions of high dose rate (HDR) brachytherapy at week 4 or 5. Patients also receive triapine intravenously (IV) over 120 minutes on day 1 and orally (PO) on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo magnetic resonance imaging (MRI) and FDG-PET/CT during follow-up.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- University of Alabama at Birmingham Cancer Center
-
-
California
-
Los Angeles, California, Förenta staterna, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Förenta staterna, 90033
- Los Angeles General Medical Center
-
Pasadena, California, Förenta staterna, 91105
- Keck Medical Center of USC Pasadena
-
-
Kansas
-
Fairway, Kansas, Förenta staterna, 66205
- University of Kansas Clinical Research Center
-
Kansas City, Kansas, Förenta staterna, 66160
- University of Kansas Cancer Center
-
Overland Park, Kansas, Förenta staterna, 66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood, Kansas, Förenta staterna, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40536
- University of Kentucky/Markey Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- University of Michigan Rogel Cancer Center
-
Detroit, Michigan, Förenta staterna, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Förenta staterna, 48334
- Weisberg Cancer Treatment Center
-
-
New Jersey
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Rutgers Cancer Institute of New Jersey
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- UPMC Hillman Cancer Center
-
-
Virginia
-
Charlottesville, Virginia, Förenta staterna, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Förenta staterna, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Patient has a new, untreated histologic diagnosis of stage IB2 (> 5 cm), II, IIIB, IIIC or IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix or stage II-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the vagina not amenable to curative surgical resection alone; the presence or absence of lymph node metastasis will be based on pre-therapy 18F-FDG PET/CT; the patient must be able to tolerate imaging requirements of an 18F-FDG PET/CT scan
-
Age >= 18 years old
-
Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
-
Life expectancy greater than 6 months
-
Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
-
Platelets >= 100 x 10^9/L
-
Hemoglobin (Hgb) >= 10.0 g/dL (blood transfusions to reach this amount are allowed)
-
Serum creatinine =< 1.5 mg/dL to receive weekly cisplatin
- If serum creatinine is between 1.5 and 1.9 mg/dL, patients are eligible for cisplatin if the estimated creatinine clearance (CCr) is > 30 ml/min (for the purpose of estimating the CCr, the formula of Cockcroft and Gault for females should be used)
-
Total serum bilirubin =< 1.5 x upper limit of normal (ULN) (in patients with known Gilbert syndrome, a total bilirubin =< 3.0 x ULN, with direct bilirubin =< 1.5 x ULN)
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
-
Able to take oral medication
-
Not pregnant and not breastfeeding; the effects of triapine on the developing human fetus are unknown; for this reason as well as because heterocyclic carboxaldehydethiosemicarbazones and radiation are known to be teratogenic, women of child-bearing potential and men must agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; patient must have documented negative urine pregnancy test must be resulted within 7 days before initiating protocol therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with triapine, breastfeeding should be discontinued if the mother is treated with triapine; these potential risks may also apply to other agents used in this study
-
For HIV and hepatitis B/C (HEPB/C):
- HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for the dose escalation portion of this trial; for those patients who are enrolled in the HIV positive (+) expansion cohort, they must be HIV infected and be on retroviral therapy with an undetectable viral load within 6 months of enrollment
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured; for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Able to understand and willingness to sign a written informed consent document
Exclusion Criteria:
- Patient has had a prior invasive malignancy diagnosed within the last three years (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix)
- Patients are excluded if they have received prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician
- Patients receiving any other investigational agents
- Patients with known glucose-6-phosphate dehydrogenase deficiency (G6PD) are excluded due to an inability to administer the antidote for methemoglobinemia, methylene blue; pre-registration testing for G6PD is at the investigator's discretion and is not required for study enrollment
- Patients who are taking any medication associated with methemoglobinemia; medication must be discontinued and must have a washout period of 4 halflives or 4 weeks, whichever is shorter
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately controlled hypertension; significant pulmonary disease including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with uncontrolled diabetes mellitus (fasting blood glucose controlled by medication, =< 200 mg/dL allowed)
- Patients who have had a hysterectomy or are planning to have an adjuvant hysterectomy following radiation as part of their cervical cancer treatment are ineligible
- Patients scheduled to be treated with adjuvant consolidation chemotherapy at the conclusion of their standard chemoradiation
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment (triapine, chemoradiation)
Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up. |
Given IV
Andra namn:
Undergo MRI
Andra namn:
Correlative studies Undergo collection of blood samples
Andra namn:
Undergo IMRT
Andra namn:
Undergo FDG-PET/CT
Andra namn:
Undergo FDG-PET/CT
Andra namn:
Undergo LDR brachytherapy
Andra namn:
Undergo pelvic EBRT
Andra namn:
Undergo FDG-PET/CT
Andra namn:
Undergo HDR brachytherapy
Andra namn:
Given IV and PO
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Eliminationshalveringstid (t 1/2)
Tidsram: Upp till 24 timmar efter dosering
|
Upp till 24 timmar efter dosering
|
|
|
Maximum Tolerated Dose (MTD)
Tidsram: Up to 5 weeks
|
The MTD was determined following a standard 3+3 design is as follows: Escalation at 0/3 DLTs, dose-reduction if >1/3 DLT, and expansion to 6 if 1/3 DLTs. DLT is defined as the severe toxicity event that leads to the termination of the treatment as defined in section 5.5. The highest dose level where <2/6 DLTs are observed will be declared MTD |
Up to 5 weeks
|
|
Number of Patients Who Experienced a DLT
Tidsram: Up to 5 weeks
|
Number of patients that experienced a DLT, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. DLTs are defined as the following adverse events if considered at least "possibly related" to a component of the study therapy and which occur from the start of treatment until completion of EBRT, prior to initiation of brachytherapy (i.e. the first 5 weeks if no treatments are missed): Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 3 toxicity not resolved with maximal intervention to Grade 0-2 over 7 days (except alopecia and fatigue); Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 4 toxicity; Any other non-hematologic toxicity ≥Grade 3; Any hematologic toxicity of ≥ Grade 4; Grade ≥3 dyspnea; Inability to deliver at least 20 of the scheduled 25 administrations of triapine at the planned dose, allowing for 2 weeks to make up missed radiation days. Inability to deliver |
Up to 5 weeks
|
|
Bioavailability of Triapine
Tidsram: Up to 2 weeks
|
The oral bioavailability of the oral form of the triapine will be measured as a numeric value using mass spectrophotometry. |
Up to 2 weeks
|
|
Cmax
Tidsram: Up to 24 hours after dosing
|
Maximum concentration |
Up to 24 hours after dosing
|
|
Tmax
Tidsram: Up to 24 hours after dosing
|
Time to maximum concentration, |
Up to 24 hours after dosing
|
|
AUC
Tidsram: Up to 24 hours after dosing
|
Area Under the Concentration-Time Curve (AUC 0-last) |
Up to 24 hours after dosing
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Fludeoxyglucose F18-Positron Emission Tomography Computed Tomography Metabolic Complete Response (mCR) Rate
Tidsram: At 3 months post-treatment
|
The mCR rate at recommended phase 2 dose, defined as a metabolic complete response on PET/CT will be defined as greater than -66% reduction in tumor FDG uptake at sites of abnormal tumor FDG uptake noted on pre-treatment FDG-PET study (considering normal cardiac or liver blood pool). |
At 3 months post-treatment
|
|
Clinical Overall Response Rate
Tidsram: 3 months post-treatment
|
Clinical response at the recommended phase 2 dose per RECIST v1.1 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. |
3 months post-treatment
|
|
Progression Free Survival (PFS)
Tidsram: Up to 4 years and 2 months from start of treatment
|
Median number of months that patients survive without disease progression from end of treatment. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 4 years and 2 months from start of treatment
|
|
Overall Survival (OS)
Tidsram: Up to 4 years and 2 months from start of treatment
|
Median number of months that patients remain alive after end of treatment. |
Up to 4 years and 2 months from start of treatment
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Sarah E Taylor, University of Pittsburgh Cancer Institute LAO
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Beräknad)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Livmodersjukdomar
- Genitala sjukdomar, kvinnor
- Genitala neoplasmer, hona
- Livmoderhalssjukdomar
- Uterina neoplasmer
- Uterina cervikala neoplasmer
- Undersökningstekniker
- Terapeutik
- Kliniska laboratorietekniker
- Diagnostiska tekniker och procedurer
- Diagnos
- Kolhydrater
- Fysiska fenomen
- Oorganiska kemikalier
- Klorföreningar
- Kväveföreningar
- Element
- Metaller
- Organisationer
- Hälsovårdsekonomi och organisationer
- Kemitekniker, analytiska
- Spektrumanalys
- Metaller, tunga
- Platinaföreningar
- Strålbehandling
- Deoxyglukos
- Deoxysocker
- Övergångselement
- Strålbehandling, konform
- Strålbehandling, datorassisterad
- Fluorodeoxiglukos F18
- Cisplatin
- 1,2-diaminocyklohexanplatina II-citrat
- Strålning
- Kongresser som ämne
- Provhantering
- Magnetresonansspektroskopi
- Platina
- Strålbehandling, intensitetsmodulerad
- Brachyterapi
- 3-aminopyridin-2-karboxaldehyd tioicarbazon
Andra studie-ID-nummer
- NCI-2015-01907
- NCI-2015-01907 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- HCC 15-157
- UPCI 15-157
- 15-157
- 9892 (Annan identifierare: CTEP)
- UM1CA186690 (U.S.S. NIH-anslag/kontrakt)
- 9892 (Annan identifierare: UPMC Hillman Cancer Center LAO)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .